Overview
- Results from the CNS-101 study showed that Cumulus Neuroscience’s NeuLogiq® Platform was feasible and well tolerated for home use over 52 weeks.
- Patients with mild Alzheimer’s disease dementia completed 99.7% of initiated sessions and achieved 77% protocol adherence.
- The findings support the use of frequent, home-based digital biomarkers to improve measurement in Alzheimer’s disease clinical trials.
The News
Cumulus Neuroscience has published final results from its CNS-101 study in Frontiers in Digital Health, demonstrating the feasibility of using the NeuLogiq Platform at home for 52 weeks among people living with mild Alzheimer’s disease dementia.
The study enrolled 119 participants across seven UK clinical sites, including 59 people with mild Alzheimer’s disease dementia and 60 age-matched healthy controls. Participants with dementia achieved 77% adherence to the full protocol and completed 99.7% of the sessions they initiated, compared with 88.8% protocol adherence among healthy controls. However, confidence in using the technology was lower among participants with dementia, at 31.6%, and some minor technical challenges occurred during initial home setup.
The NeuLogiq Platform combines a wireless EEG headset with tablet-based cognitive assessments and cloud infrastructure to capture data across cognition, EEG, mood, speech, and sleep. The feasibility study supports the use of frequent, home-based digital biomarkers to complement traditional Alzheimer’s assessments and potentially enable more sensitive, lower-burden clinical trials.
Industry Perspective
Alzheimer’s disease trials have traditionally relied on periodic, clinic-based cognitive assessments that may miss subtle changes between visits. Home-based digital biomarkers could provide more frequent and objective data while reducing the burden of repeated clinical assessments for patients and caregivers.
Strategic Impact
The CNS-101 results strengthen Cumulus Neuroscience’s position in digital biomarker-enabled clinical research and demonstrate the feasibility of long-term, unsupervised monitoring in patients with mild dementia. By enabling frequent collection of cognitive and physiological data in real-world settings, the NeuLogiq Platform could help support more sensitive clinical trials and potentially improve the efficiency of future Alzheimer’s disease research.
Source: PRnewswire
